Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 4
2006 1
2009 2
2010 3
2011 3
2012 6
2013 3
2014 7
2015 12
2016 10
2017 7
2018 8
2019 9
2020 8
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31895609

75 results

Results by year

Filters applied: . Clear all
Page 1
Reply to T. Tanaka et al and F. Liang.
Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Prabhash K. Noronha V, et al. J Clin Oncol. 2020 Mar 10;38(8):844-846. doi: 10.1200/JCO.19.02974. Epub 2020 Jan 2. J Clin Oncol. 2020. PMID: 31895609 No abstract available.
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.
Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Noronha V, et al. J Clin Oncol. 2020 Jan 10;38(2):124-136. doi: 10.1200/JCO.19.01154. Epub 2019 Aug 14. J Clin Oncol. 2020. PMID: 31411950 Clinical Trial.
A new standard for EGFR-mutant NSCLC?
Killock D. Killock D. Nat Rev Clin Oncol. 2019 Oct;16(10):593. doi: 10.1038/s41571-019-0271-8. Nat Rev Clin Oncol. 2019. PMID: 31471565 No abstract available.
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
Han B, Jin B, Chu T, Niu Y, Dong Y, Xu J, Gu A, Zhong H, Wang H, Zhang X, Shi C, Zhang Y, Zhang W, Lou Y, Zhu L, Pei J. Han B, et al. Int J Cancer. 2017 Sep 15;141(6):1249-1256. doi: 10.1002/ijc.30806. Epub 2017 Jun 21. Int J Cancer. 2017. PMID: 28560853 Free article. Clinical Trial.
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Hosomi Y, et al. J Clin Oncol. 2020 Jan 10;38(2):115-123. doi: 10.1200/JCO.19.01488. Epub 2019 Nov 4. J Clin Oncol. 2020. PMID: 31682542 Clinical Trial.
75 results